← All trials
NCT02849613
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2016
- Primary completion
- Sep 30, 2017
- Completion date
- Sep 30, 2017
- First posted
- Jul 29, 2016
- Last posted
- Oct 6, 2021
- Enrollment
- 0
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of GrenobleLead sponsor
- Andaluz Health ServiceCollaborator
- Assistance Publique - Hôpitaux de ParisCollaborator
- University of Franche-ComtéCollaborator
- Etablissement Français du SangCollaborator
- University of BarcelonaCollaborator
- Instituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL)Collaborator
- Histocell S.L.Collaborator
- European CommissionCollaborator
- University of LyonCollaborator
- Universidad Autonoma de BarcelonaCollaborator
- Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaCollaborator
- Institut National de la Santé Et de la Recherche Médicale, FranceCollaborator
- MedfilesCollaborator
- NovadiscoveryCollaborator
- Government of FinlandCollaborator
- Servicio de Salud de Castilla La Mancha (SESCAM)Collaborator
- Spanish National Health SystemCollaborator
- Masaryk UniversityCollaborator
- University of TampereCollaborator
- University of GrenobleCollaborator
- University of BordeauxCollaborator
- University of Caen-NormandieCollaborator
- University of ToulouseCollaborator
- University of Eastern FinlandCollaborator
- University of GlasgowCollaborator
- Universidad Autonoma de MadridOfficial
- FinovatisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.